Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | AOC1 | P19801 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084512 | 0.81 | KAT2B (0.37) | KAT2BNR4A2GAATDP1PIK3CD | |
| SCHEMBL1621716 | 0.81 | KAT2B (0.37) | KAT2BIRAK4NR4A2GAATDP1 | |
| SCHEMBL12393156 | 0.77 | CHUK (0.39) | KAT2BGAAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL20688201 | 0.77 | TYK2 (0.43) | KAT2BIRAK4NR4A2AOC1AOC3 | |
| SCHEMBL14243611 | 0.77 | SMN1; SMN2 (0.44) | GAA | |
| SCHEMBL3669943 | 0.75 | LRRK2 (0.38) | KAT2BIRAK4 | |
| SCHEMBL3644982 | 0.73 | PIK3CD (0.34) | KAT2BIRAK4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20697016 | 0.72 | TYK2 (0.44) | — | |
| SCHEMBL8007654 | 0.72 | CRHR1 (0.48) | IRAK4GAATDP1 | |
| SCHEMBL15781884 | 0.71 | PDE10A (0.41) | GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | KAT2B 3639/4885IRAK4 1155/4885NR4A2 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.